Company news
Nuvo Pharmaceuticals Inc news in 2014
Nuvo Pharmaceuticals Inc's news releases, calls and decks from 2014, newest first.
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10(TM)
December 22, 2014
Nuvo Research® reports that all patients have completed Phase 2 study of WF10(TM) for the treatment of allergic rhinitis
December 18, 2014
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel
November 13, 2014
Nuvo Research® Announces 2014 Third Quarter Results
November 10, 2014
Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
November 3, 2014
Nuvo Research® Completes WF10(TM) U.S. Market Study for Treatment of Refractory Allergies
October 22, 2014
Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma
October 17, 2014
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals
September 8, 2014
Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference
September 4, 2014
Nuvo Research® Completes Enrolment in WF10(TM) Phase 2 Clinical Trial
September 3, 2014
Nuvo Research® announces 2014 second quarter results
July 30, 2014
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference
June 17, 2014
Nuvo Research announces director election results of its annual general meeting
June 11, 2014
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5%
May 29, 2014
Nuvo Research® announces 2014 first quarter results
April 30, 2014
Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
April 23, 2014
Nuvo Research® closes $3.1 million private placement
April 1, 2014
Nuvo Research announces 2013 fourth quarter & year-end results
February 20, 2014
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt
February 10, 2014
Nuvo Research Announces FDA Approval of PENNSAID® 2%
January 17, 2014